US Patent

US9884054 — Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Method of Use · Assigned to Aragon Pharmaceuticals Inc · Expires 2033-09-23 · 7y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.

USPTO Abstract

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.

Drugs covered by this patent

Erleada (apalutamide) · Johnson & Johnson

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2237`	—	Erleada
`U-2237`	—	Erleada

Patent Metadata

Patent number: US9884054
Jurisdiction: US
Classification: Method of Use
Expires: 2033-09-23
Drug substance claim: No
Drug product claim: No
Assignee: Aragon Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.